Cargando…
Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies
In the last two decades, biologicals have become essential in treating children and adolescents with inflammatory bowel disease. TNF-α inhibitors (infliximab, adalimumab and golimumab) are preferentially used. Recent studies suggest that early application of TNF-α inhibitors is beneficial to inducin...
Autores principales: | Claßen, Merle, Hoerning, André |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136755/ https://www.ncbi.nlm.nih.gov/pubmed/37189883 http://dx.doi.org/10.3390/children10040634 |
Ejemplares similares
-
Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease – Data from the multicenter CEDATA-GPGE registry study
por: Claßen, Merle, et al.
Publicado: (2022) -
IL-23 Monoclonal Antibodies for IBD: So Many, So Different?
por: McDonald, Benjamin D, et al.
Publicado: (2022) -
Special Issue: Monoclonal Antibodies
por: Klein, Christian
Publicado: (2018) -
Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient
por: Nones, Rodrigo Bremer, et al.
Publicado: (2021) -
Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC)
por: Jentzer, Alexandre, et al.
Publicado: (2020)